All In Biotech

Drug Trial Radar · NCT06038279

Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.

A Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

Jul 4, 2023

Primary completion

Sep 5, 2024

Study completion Sep 5, 2024

Sponsor

Lead sponsor
Inimmune CorporationIndustry
Sponsor type
Industry
Collaborators
Avance Clinical Pty Ltd.
First posted
Sep 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses. This study will be conducted in two parts: Phase I single ascending dose (SAD) and Phase Ib multiple ascending dose (MAD).

Conditions

  • Allergic Rhinitis Due to Weed Pollen
  • Allergic Rhinitis

Interventions

  • INI-2004Drug

    INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

  • PlaceboDrug

    The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and relationship of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to discontinuation of study treatment after a single ascending Dose (SAD)Time frame: Baseline, Day 1 then daily through to Day 7 End of Study Visit
  2. Incidence, severity and relationship of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to discontinuation of study treatment after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14, 21, 28, 35 through to Day 58 End of Study Visit
  3. Number of Participants with a Change from baseline in Vital signs measurements after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  4. Number of Participants with a Change from baseline in Vital signs measurements after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  5. Change from baseline in 12-lead electrocardiogram parameters after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  6. Change from baseline in 12-lead electrocardiogram parameters after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  7. Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)Time frame: Baseline, Day 2 through to Day 7 End of Study Visit
  8. Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)Time frame: Baseline, Day 2 through to Day 7 End of Study Visit
  9. Number of Participants with a Change from baseline in Clinical laboratory results after a single ascending Dose (SAD)Time frame: Baseline, Day 2 through to Day 7 End of Study Visit
  10. Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit
  11. Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit
  12. Number of Participants with a Change from baseline in Clinical laboratory results after multiple ascending doses (MAD)Time frame: Baseline = Day 0, Day 14 and Day 58 End of Study Visit
  13. Change from baseline in Nasal symptoms after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  14. Change from baseline in Nasal symptoms after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  15. Change from baseline in Nasal irritancy after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  16. Change from baseline in Nasal irritancy after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  17. Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  18. Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  19. Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  20. Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  21. Change from baseline in Spirometry after a single ascending Dose (SAD)Time frame: Baseline, Day 1 through to Day 7 End of Study Visit
  22. Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  23. Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  24. Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  25. Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit
  26. Change from baseline in Spirometry after multiple ascending doses (MAD)Time frame: Baseline = Day 0 through to Day 58 End of Study Visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.